Global Neuroendocrine Tumor Treatment Markets, Trends, Competition, Opportunity and Forecast, 2028F - Advancements in Neuroendocrine Tumor Treatments Spur Market Expansion

DUBLIN, Aug. 8, 2023 /PRNewswire/ -- The "Neuroendocrine Tumor Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Product Analysis, By Site Analysis, By End User, By Region and Competition" report has been added to ResearchAndMarkets.com's offering.

Global neuroendocrine tumor treatment market is anticipated to experience growth to 2028

This can be attributed to the rising prevalence of neuroendocrine tumors across the globe. The incidence of neuroendocrine tumors has increased notably in the past three to four decades, according to an article published in the Journal of Cancers in April 2022, titled "Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)".

Neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC) disease, multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), and Von Hippel-Lindau syndrome (VHL) can be owed to the increased prevalence of neuroendocrine tumor (NET). In the United States, more than 12,000 people are diagnosed with a neuroendocrine tumor per year, and around 175,000 people are living with it, according to the most recent American Society of Clinical Oncology Neuroendocrine Tumor Statistics, which was updated in February 2022.

Carcinoid tumor, which typically manifests in the gastrointestinal tract (GIT) or the lungs, affects between 3,000 and 30,000 persons in the United States, according to data updated in November 2021 by the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center. The high frequency of neuroendocrine cancer patients worldwide is anticipated to contribute to the market's growth.

The treatment techniques for neuroendocrine tumors such as targeted therapy, radionuclide treatment, somatostatin analogs, immunotherapy, CAR-T-Cell therapy, INF, trans arterial treatment, vaccines, bispecific antibodies, and cytotoxic chemotherapy of highly differentiated and low differentiated G1 and G2 GEP neuroendocrine tumor treatments (NETs) have also observed innovations in the past few years.

This advancement in treatment techniques has led to a robust improvement in the growth of the neuroendocrine tumor treatment market. 

Increased Government Initiatives

The governments of many developed nations like the United States are raising funds for research in cancer to assist in its diagnosis as well as treatment. The government is also funding numerous clinical trials to encourage companies to develop successful and effective cancer treatments. For instance, with federal government funding in cancer research, which is essential to assuring a future free of cancer, the American Institute for Cancer Research has financed almost USD110 million in research as of April 2021.

Additionally, under the 2021 Rare Cancers, Rare Illnesses and Unmet Need (RCRDUN) grant opportunity, The Department of Health of the Commonwealth of Australia January 2022 announced the availability of a grant for the study of rare cancers and rare diseases for USD 63.4 million.

Moreover, for the project `Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumor: the AUS-NET Trial,` Flinders University specifically obtained USD 2,374,220.10 in funding. Also, USD 1.5 million was invested by The Neuroendocrine Tumor Research Foundation (NETRF) for the development of Peptide Receptor Radionuclide Therapy (PRRT), an advanced radiation therapy.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global neuroendocrine Tumor treatment market.

• F Hoffmann-La Roche AG
• Bristol-Myers Squibb Co
• Eli Lilly & Co
• Novartis AG
• Pfizer Inc
• Amgen Inc
• Exelixis Inc
• Teva Pharmaceutical Industries Ltd
• AVEO Pharmaceuticals Inc
• Hutchison MediPharma Ltd

Market Dynamics

Drivers

• Developments and Approval of Novel Drugs
• Use of Artificial Intelligence (AI) in Treatment Techniques
• Increased Government and Company's' Initiatives

Market Trends & Developments

• Upcoming Patient Assistance Programs (PAPs)
• Ongoing Clinical Trials and R&D Programs
• Adoption of Next-Generation Sequencing Techniques

Challenges

• High Cost of the Treatment
• Associated Side Effects of the Treatment
• Stringent Regulatory Framework

Clinical Trial Analysis

• Ongoing Clinical Trials
• Completed Clinical Trials
• Terminated Clinical Trials
• Breakdown of Pipeline, By Development Phase
• Breakdown of Pipeline, By Status
• Breakdown of Pipeline, By Site Analysis
• Breakdown of Pipeline, By Region
• Clinical Trials Heat Map

Report Scope:

Neuroendocrine Tumor Treatments Market, By Product Analysis:

• Somatostatin Analogs (SSA)
• Targeted Therapy
• Others

Neuroendocrine Tumor Treatments Market, By Site Analysis:

• Lungs
• Pancreas
• Colon
• Small Intestine
• Others

Neuroendocrine Tumor Treatments Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Neuroendocrine Tumor Treatments Market, By Region:

• Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia
• Europe
• France
• Germany
• United Kingdom
• Italy
• Spain
• North America
• United States
• Mexico
• Canada
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

For more information about this report visit https://www.researchandmarkets.com/r/s2j5rz

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets